Live data from Hacker News

Viewing profile — biols

biols

HN member
Joined
Thu, Mar 14, 2019, 1:51 AM UTC
HN karma
72
Public activity
11 items

About biols

No profile information was provided.

Recent public activity

  1. comment
    Comment #32396835

    Yes!! I and my colleagues and probably everyone I went to graduate school with would love a resource like that. I'd be happy to help promote and/or contribute articles / papers I'm…

  2. comment
    Comment #32386598

    Side question: does anybody know of a Hacker News type aggregator for biotech which isn't fuddy-duddy or paid? Sites like STAT+ and Fierce Biotech usually feel more focused on busi…

  3. comment
    Comment #31667897

    Putting "gay-everything in your face at every corner" next to "obvious hard core drug abuse on the sidewalks" could be misconstrued as homophobic, which I hope wasn't your intentio…

  4. comment
    Comment #30258418

    I'd be very happy to participate in those type of projects. One could even imagine that pharma companies could be _mandated_ to spend a certain number of people-hours on R&D in a r…

  5. comment
    Comment #30253893

    I agree that the system is just "reality" right now. I think the idea of a cryptographic data commons is an interesting idea, I'm just trying to imagine how it'd play out in my day…

  6. comment
    Comment #30253831

    I think the idea would have been that Pfizer and Moderna could have pooled resources and made a single optimal vaccine faster, though I'll admit I'm not sure it could have happened…

  7. comment
    Comment #30253421

    The Broad Institute hosts a very interesting transcriptomic dataset called CMap [1] that was intended to facilitate rapid drug repurposing. Having studied this dataset and worked w…

  8. comment
    Comment #30253389

    This is what I'd like to see. There should be some kind of system where in-progress research being done by pharma companies can be published. This would reduce the massively redund…

  9. comment
    Comment #30253352

    Major pharma companies are all constantly competing, and very often are duplicating work because they are not sharing major experimental results. The way it feels is that there's a…

  10. comment
    Comment #30251575

    I work at a medium-sized pharmaceutical company as a computational biologist. Diseases like KS sometimes come up as potential repurposing targets (or novel drug targets), but we ge…

  11. comment
    Comment #19385863

    There's the 20/20/20 rule (every 20 minutes, look at something 20 feet away for 20 seconds) that's cited often. I started to have similar issues, and my optometrist set me up with …